Contact
Leslie L. Citrome, M.D., M.P.H., is a distinguished life fellow of the American Psychiatric Association and a fellow of the American Society of Clinical Psychopharmacology, where he currently serves as immediate past president. He is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. In 2019, Dr. Citrome received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science)”. In 2018, 2021, and 2023, Dr. Citrome was recognized as the Voluntary Faculty Teacher of the Year in the Department of Psychiatry and Behavioral Sciences at New York Medical College/Westchester Medical Center.
Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of the number needed to treat and the number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australia. Dr. Citrome’s main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is an author and co-author of more than 600 research reports, reviews, and chapters in the scientific literature. He is a member of the Board of Directors of the World Association of Medical Editors. Dr. Citrome is editor-in-chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; and also serves as an editorial board member for 11 other journals.
Education
- Residency, Psychiatry, New York University
- M.D., McGill University Faculty of Medicine
- M.P.H., Columbia University School of Public Health
- DEC, Pure and Applied Science, Dawson College
Areas of Expertise
- Mental Health Disorders
Publications
- Gupta M, D'Souza VC, Citrome L, et. al. "Mosaic Turner Syndrome and Treatment-Resistant Schizophrenia." The primary care companion for CNS disorders, 27(5), (2025) . pii: 25cr03980. doi: 10.4088/PCC.25cr03980
- Howes OD, Bukala BR, Chen EYH, et. al. "Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them." The American journal of psychiatry, (), (2025) appiajp20241040. doi: 10.1176/appi.ajp.20241040
- Kane JM, Agid O, Castle DJ, et. al. "The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment." Neurology and therapy, (), (2025) . doi: 10.1007/s40120-025-00838-3
- Correll CU, Mafi CE, Fagiolini A, et. al. "Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment." Neuropsychiatric disease and treatment, 21(), (2025) 1857-1883. doi: 10.2147/NDT.S539306
- Chepke C, Weiden PJ, Citrome L, et. al. "Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia." Expert opinion on drug metabolism & toxicology, 21(9), (2025) 1041-1047. doi: 10.1080/17425255.2025.2545918
- Citrome L. "Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide." CNS spectrums, 30(1), (2025) e73. doi: 10.1017/S1092852925100400
- Kishi T, Ikuta T, Citrome L, et. al. "Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis." Translational psychiatry, 15(1), (2025) 211. doi: 10.1038/s41398-025-03439-8
Memberships and Affiliations
- Distinguished Life Fellow of the American Psychiatric Association
- Fellow of the American Society of Clinical Psychopharmacology
- Fellow (Emeritus), Collegium Internationale Neuro-Psychopharmacologicum (CINP)
